ACE Report #8856
Ace Report Cover Osteoarthritis

OARSI 2016: Chondroitin sulfate reduces cartilage volume loss vs. celecoxib in knee OA

Study Type:Therapy
OE Level Evidence:N/A
Journal Level of Evidence:N/A

In a two-year double-blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients

Contributing Authors: J Pelletier J Raynauld A Beaulieu L Bessette F Morin A Fernandes F Abram M Dorais J Matel-Palletier

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.


194 patients with knee osteoarthritis were randomized to undergo treatment once a day for 24 months with either 1200mg chondroitin sulfate or 200mg celecoxib. The study was conducted in order to investigate suggestions in prior studies that chondroitin sulfate provides benefits in preserving the integrity of cartilage and slowing its progressive deterioration. The findings of this study displayed ...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.